10.2 Antiplatelets, Anticoagulants & Lipid Drugs

10.2 Antiplatelets, Anticoagulants & Lipid Drugs

Quick Answer: Antiplatelets target platelet activation/aggregation (COX-1, P2Y12, GP IIb/IIIa). Anticoagulants interrupt thrombin generation or thrombin itself (heparins via ATIII, warfarin via vitamin K–dependent factors, DOACs via Xa or IIa). Thrombolytics dissolve formed fibrin. Lipid drugs reduce atherogenic lipoproteins mainly by HMG-CoA reductase inhibition (statins), reduced intestinal cholesterol uptake (ezetimibe), increased LDL-receptor activity (PCSK9 inhibitors), or triglyceride-focused PPAR-α activation (fibrates).

CBSE stems rarely ask for brand recall alone. They ask which step is blocked, which lab is affected, or which adverse effect is mechanistically expected (heparin-induced thrombocytopenia pathway, warfarin skin necrosis with protein C deficiency conceptual, statin myopathy, niacin flush).

Hemostasis Context: Platelets vs Coagulation Cascade

Primary hemostasis forms the platelet plug; secondary hemostasis stabilizes it with fibrin. Antiplatelet drugs are central in arterial disease (ACS, coronary stents, secondary stroke prevention in many settings). Anticoagulants are central in venous thromboembolism, atrial fibrillation stroke prevention, and many ACS adjunctive strategies. Knowing this anatomic/physiologic split prevents choosing warfarin when the vignette is pure platelet-driven coronary plaque thrombosis without a clear anticoagulant indication.

Aspirin: Irreversible COX-1 Inhibition

Aspirin acetylates cyclooxygenase-1 (COX-1) irreversibly in platelets. Platelets cannot synthesize new COX-1 (anucleate), so thromboxane A2 (TXA2) production remains suppressed for the platelet lifespan (~7–10 days). TXA2 normally promotes aggregation and vasoconstriction; blocking it yields an antithrombotic effect at low doses. Higher doses also inhibit endothelial COX-2–derived prostacyclin more, which is one reason low-dose strategies are used for antiplatelet effect.

High-yield adverse effects: GI mucosal injury/bleeding, hypersensitivity (including aspirin-exacerbated respiratory disease in susceptible patients), and Reye syndrome risk in children with viral illness (classic teaching). Aspirin does not require monitoring of a coagulation time the way heparin/warfarin do; bleeding risk is clinical.

P2Y12 Inhibitors

ADP released from dense granules amplifies aggregation via the P2Y12 receptor → Gi signaling → ↓ cAMP → increased activation of downstream aggregation pathways. P2Y12 inhibitors block this amplification.

Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) is foundational after coronary stenting because platelet-rich thrombi threaten stent thrombosis. Exam angles: prodrug activation, bleeding risk when combined with anticoagulants, and that these drugs are antiplatelet—not the same as Xa inhibitors.

Glycoprotein IIb/IIIa Inhibitors

GP IIb/IIIa (integrin αIIbβ3) is the final common pathway for platelet aggregation: activated GP IIb/IIIa binds fibrinogen (and vWF) to cross-link platelets. Inhibitors (abciximab, eptifibatide, tirofiban conceptually) block this step and are potent IV antiplatelet agents used in selected ACS/PCI contexts. Major risk is bleeding and thrombocytopenia (especially abciximab-related immune thrombocytopenia teaching points).

Mechanism hierarchy to remember:

1. Aspirin ↓ TXA2 synthesis (COX-1).
2. P2Y12 inhibitors ↓ ADP amplification.
3. GP IIb/IIIa inhibitors block fibrinogen bridging (final aggregation step).

Heparin, LMWH, and Fondaparinux: Antithrombin Pathway

Unfractionated heparin (UFH) binds antithrombin III (ATIII) and conformationally accelerates ATIII inhibition of thrombin (IIa) and factor Xa (and other serine proteases). A long pentasaccharide sequence plus sufficient chain length is needed for simultaneous ATIII–thrombin bridging; shorter chains favor Xa inhibition.

Low-molecular-weight heparins (LMWH) (enoxaparin, dalteparin) preferentially anti-Xa over anti-IIa because chains are shorter. More predictable pharmacokinetics; often no routine aPTT monitoring (anti-Xa levels in special populations).

Fondaparinux is a synthetic pentasaccharide that catalyzes ATIII-mediated Xa inhibition almost exclusively (no meaningful thrombin inhibition via bridging).

HIT (heparin-induced thrombocytopenia) is a high-yield immune complication: antibodies (often IgG) against platelet factor 4 (PF4)–heparin complexes activate platelets via Fc receptors → thrombocytopenia and paradoxical thrombosis. Management requires stopping all heparin and using a non-heparin anticoagulant—not platelet transfusion as first instinct for "low platelets."

Warfarin and the Vitamin K Cycle

Warfarin inhibits vitamin K epoxide reductase (VKORC1), preventing regeneration of reduced vitamin K needed as a cofactor for γ-carboxylation of clotting factors II, VII, IX, X and regulatory proteins C and S. Without γ-carboxylation, these proteins are dysfunctional.

Because factor VII and protein C have short half-lives, early warfarin can create a transient hypercoagulable imbalance—especially if large loading doses are used in protein C deficiency—classic setup for warfarin-induced skin necrosis teaching cases. Bridge with heparin when rapid anticoagulation is required until factor II (long half-life) is adequately suppressed.

Monitor with INR/PT. Many drug–diet interactions: CYP2C9 inhibitors/inducers, vitamin K intake, antibiotics altering gut vitamin K. Reverse with vitamin K ± PCC/FFP depending on urgency and bleeding. Teratogenicity is a critical counseling point (warfarin embryopathy).

DOACs: Direct Xa Inhibitors vs Dabigatran

Direct oral anticoagulants simplify chronic anticoagulation for many nonvalvular AF and VTE indications.

Compared with warfarin: fewer dietary interactions, fixed dosing in many protocols, no routine INR—but renal clearance matters (especially dabigatran), and mechanical valves remain a warfarin domain in standard teaching. Andexanet alfa is used conceptually for Xa inhibitor reversal in major bleeding contexts; know that DOACs are not interchangeable with antiplatelets.

Thrombolytics

Thrombolytics (alteplase/tPA, tenecteplase, reteplase, streptokinase historically) convert plasminogen → plasmin, which cleaves fibrin. They are used for selected STEMI (when PCI is unavailable in time), acute ischemic stroke within time windows, and some massive PE cases—always balancing life-threatening thrombosis against catastrophic hemorrhage (especially intracranial).

Exam distinction: thrombolytics lyse clot; anticoagulants prevent propagation; antiplatelets reduce platelet aggregation. Mixing these roles is a common wrong-answer pathway.

Statins: HMG-CoA Reductase Inhibition

Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA → mevalonate in hepatic cholesterol synthesis. Reduced hepatocyte cholesterol upregulates LDL receptors, increasing clearance of circulating LDL. Statins also have "pleiotropic" effects (endothelial function, plaque stabilization) often cited in ACS secondary prevention.

High-yield adverse effects:

• Myalgias, myopathy, rare rhabdomyolysis (↑ CK; risk ↑ with drug interactions, especially strong CYP3A4 inhibitors with simvastatin/lovastatin).
• Transaminase elevations.
• Small increase in diabetes incidence signals in large populations—still net CV benefit in indicated patients.
• Avoid in pregnancy (developmental cholesterol needs teaching).

Mevalonate pathway intermediates also feed prenylation and coenzyme Q concepts occasionally tested at basic level; the core Step-style fact remains HMG-CoA reductase + LDL-receptor upregulation.

Fibrates, Niacin, Ezetimibe, and PCSK9

Fibrates (gemfibrozil, fenofibrate) activate PPAR-α, increasing fatty acid oxidation and LPL expression → lower triglycerides, raise HDL modestly. Risk: gallstones (↑ cholesterol excretion into bile), myopathy risk especially when combined with statins (gemfibrozil worse interaction profile than fenofibrate in classic teaching).

Niacin (vitamin B3) lowers VLDL/LDL and is the most effective older oral agent for raising HDL, but outcome benefits are limited in modern statin-era trials. Flushing is prostaglandin-mediated (often reduced by aspirin pretreatment teaching). Also: hyperglycemia, hyperuricemia, hepatotoxicity.

Ezetimibe inhibits intestinal cholesterol absorption via NPC1L1 transporter on enterocytes → less cholesterol delivery to liver → ↑ LDL receptors → ↓ LDL-C. Often combined with statins for additive LDL lowering.

PCSK9 inhibitors (monoclonal antibodies such as evolocumab, alirocumab; also siRNA inclisiran conceptually) reduce PCSK9-mediated degradation of LDL receptors. More surface LDL receptors → profound LDL-C reduction. High-yield mechanism: PCSK9 normally binds LDLR and targets it for lysosomal degradation; blocking PCSK9 recycles receptors.

Side-Effect Mechanisms That Separate Top Scores

Build rapid associations:

• Bleeding + low platelets + thrombosis after heparin → HIT (PF4–heparin antibodies).
• Skin necrosis early after warfarin → protein C imbalance / deficiency context.
• Cough is ACEI, not statin or aspirin classic.
• Flush after niacin → prostaglandins, not histamine first-line teaching (aspirin helps).
• Muscle pain + dark urine on statin ± fibrate → rhabdomyolysis workup.
• Dyspnea after ticagrelor → drug effect, not always heart failure.
• Protamine reverses UFH; incomplete for LMWH; ineffective for fondaparinux/DOACs generally.
• Vitamin K addresses warfarin pathway; it does not reverse dabigatran/Xa inhibitors.

Putting It Together for CBSE Vignettes

A patient with NSTEMI may receive aspirin + P2Y12 inhibitor ± anticoagulant—map each to platelet vs cascade. A patient with DVT may receive LMWH bridge to warfarin or a DOAC—map monitoring and targets. A patient with LDL-C above goal on statin may add ezetimibe or a PCSK9 inhibitor—map LDL-receptor biology. A patient with hypertriglyceridemia pancreatitis risk may need fibrate-focused thinking rather than ezetimibe.

If you can state for each drug (1) molecular target, (2) effect on thrombus or lipoprotein particle, and (3) one mechanism-based toxicity, you are prepared for the majority of cardiovascular pharmacology items in this domain.